EUCTR2009-012439-14-CZ进行中（未招募）不适用
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer - N/A
Astellas Pharma Global Development, Inc. (APGD)0 个研究点目标入组 100 人开始时间: 2009年11月11日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject is eligible for the study if all of the following apply:
- •1. The subject prior to any study-related procedures (including withdrawal of prohibited medicines, if applicable) has provided Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)- approved written Informed Consent and privacy language as per national regulations (e.g., HIPAA Authorization for US sites).
- •2. The subject is male or female and aged 18 years or older at the Baseline Visit with
- •metastatic breast cancer.
- •3. The subject has histologically- or cytologically-proven adenocarcinoma of the
- •breast that is HER2 negative defined as one of the following:
- •o Negative fluorescence in-situ hybridization (FISH).
- •o 0 or 1+ immunohistochemistry (IHC).
- •o IHC 2+ with negative FISH.
- •Subjects with hormone receptor positive or negative status are eligible. Additionally,
- •subjects with triple negative status (meaning estrogen receptor negative, rogesterone receptor negative and HER2 negative) are eligible.
- •4. The subject has received no prior chemotherapy regimen for metastatic breast cancer.
- •o Prior treatment with a cytotoxic therapy (other than docetaxel) is allowed if
- •administered in the neoadjuvant or adjuvant setting >3 weeks prior to the Baseline
- •Visit, with all side effects of using prior cytotoxic therapy resolved or back to
- •baseline (with the exception of weight loss or gain, anorexia, alopecia or fatigue).
- •o Prior treatment with docetaxel is allowed if administered in the neoadjuvant or
- •adjuvant setting, and the subject has no recurrent disease within 12 months after
- •completing treatment, with all side effects of prior docetaxel use resolved or back to
- •baseline (with the exception of weight loss or gain, anorexia, alopecia or fatigue).
- •o Prior treatment with a kinase inhibitor, biologic therapy, vaccine, or investigational treatment other than cytotoxic therapy or procedure for breast cancer is allowed if administered in the neoadjuvant, adjuvant or metastatic setting = 4 weeks prior to the Baseline Visit.
- •o Prior treatment with hormonal therapy in the neoadjuvant, adjuvant or metastatic setting is allowed if administered = 2 weeks prior to the Baseline Visit.
- •o Prior treatment with bevacizumab is allowed if administered in the neoadjuvant or adjuvant setting >4 weeks prior to the Baseline Visit.
- •5. Prior palliative radiation therapy is allowed if treatment was completed = 2
- •weeks prior to the Baseline Visit with side effects from radiation resolved.
- •6. The subject has an Eastern Cooperative Oncology Group (ECOG) performance
- •status = 1 at the Baseline Visit.
- •7. The subject has at least one measurable lesion by RECIST (Version 1.1).
- •o If the selected lesion(s) received prior radiation and/or loco-regional therapy,
- •there must be evidence of disease progression since the last radiation or
- •locoregional therapy.
- •8. If the subject has a previous history of non-breast cancer malignancy, the subject must meet the following criteria for a cancer survivor:
- •o Subject having a previous history of a non-invasive carcinoma is eligible if in the opinion of the Investigator, he/she has successful curative treatment anytime prior to enrollment.
- •o For all other malignacies, the subject has undergone potentially curative therapy and the subject has been considered disease free for at least 5 years.
- •9. The subject’s life expectancy is estimated to be > 12 weeks at the Baseline
排除标准
- •A subject will be excluded from participation if any of the following apply:
- •1. The subject has hypersensitivity to docetaxel or polysorbate 80.
- •2. The subject has had a major surgical procedure, substantial open biopsy, or significant traumatic injury within 28 days prior to the Baseline Visit or anticipation of need for major surgical procedure during the course of the study.
- •3. The subject has neuropathy = Grade 2 at the Baseline Visit.
- •4. The subject has inadequate marrow, hepatic and/or renal function at the Baseline Visit defined as:
- •o Serum creatinine = 1.5 x ULN or calculated serum creatinine clearance < 60
- •o ANC < 1500/mm3.
- •o Platelets = 100,000/mm3.
- •o Alanine Transaminase (ALT) or Aspartate Transaminase (AST) >2.5 x ULN, or
- •>5 x ULN in subjects who have documented liver metastases.
- •o Bilirubin > ULN.
- •o Hemoglobin <9 gm/dL
- •5. Known brain or leptomeningeal metastasis as assessed through medical history review and physical examination.
- •6. The subject has a known history of positive test for Hepatitis B surface Antigen
- •(HsbAg) or hepatitis C antibody or history of positive test for Human
- •Immunodeficiency Virus (HIV).
- •7. The subject has significant and/or uncontrolled cardiac, renal, hepatic or other
- •systemic disorders or significant psychological conditions at Baseline Visit that in
- •the Investigator’s judgment would jeopardize subject enrollment or compliance
- •with the study procedures.
研究者
相似试验
进行中（未招募）
1 期
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerAdenocarcinoma of the breast that is HER2 negative.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012439-14-BEAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
不适用
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-DEAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
不适用
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-IEAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
1 期
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-GBAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
1 期
A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced MelanomaMedDRA version: 21.1Level: PTClassification code: 10025671Term: Malignant melanoma stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025670Term: Malignant melanoma stage III Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10066600Term: Melanoma recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104Advanced MelanomaCTIS2023-507389-15-00Genentech Inc.130